Secondary syphilis occurring under anti-TNFalpha therapy

Clarisse Bories-Haffner; S Buche; Julien Paccou

doi:10.1016/j.jbspin.2010.02.023

Secondary syphilis occurring under anti-TNFalpha therapy

Joint Bone Spine. 2010 Jul;77(4):364-5. doi: 10.1016/j.jbspin.2010.02.023. Epub 2010 May 8.

Authors

Clarisse Bories-Haffner¹, S Buche, Julien Paccou

Affiliation

¹ Département universitaire de rhumatologie, centre hospitalier et universitaire, université de Lille 2, 59037 Lille, France.

PMID: 20452802
DOI: 10.1016/j.jbspin.2010.02.023

Abstract

Anti-TNF agents are remarkably effective in the treatment of chronic inflammatory rheumatism diseases. Main side effect of anti-TNF is an increased risk of infection. We report the observation of a secondary syphilis occurring under anti-TNFalpha therapy.

Publication types

Case Reports

MeSH terms

Adult
Etanercept
Female
Humans
Immunoglobulin G / adverse effects*
Immunoglobulin G / therapeutic use
Opportunistic Infections / diagnosis
Opportunistic Infections / etiology*
Penicillins / therapeutic use
Receptors, Tumor Necrosis Factor / therapeutic use
Risk Factors
Spondylitis, Ankylosing / drug therapy
Syphilis / diagnosis
Syphilis / drug therapy
Syphilis / etiology*
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Immunoglobulin G
Penicillins
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
Etanercept